Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666289 · ClinicalTrials.gov registry record
Familial Myeloproliferative Disorders
A clinical trial of Polycythemia Vera and Essential Thrombocythemia, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 17
- Enrollment target
- 6
- Study locations
NCT00666289: Completed study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Icahn School of Medicine at Mount Sinai.
NCT00666289 is a study of Polycythemia Vera and Essential Thrombocythemia that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 17 participants, below the 340-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666289, a study of Polycythemia Vera and Essential Thrombocythemia, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
- 6
- Study locations
Study Summary
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.
Conditions Studied
Study Locations (6)
New York
- Mount Sinai School of Medicine - New York
- Weill Cornell - New York
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- University of Illinois at Chicago - Chicago
Utah
- University of Utah - Salt Lake City
Other
- University of Florence - Florence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-06-20 |
What the finished NCT00666289 record still lists
NCT00666289 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 340-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Polycythemia Vera appearing as the primary indexed condition, and to 0 interventions.
NCT00666289 lists 6 locations in 5 states (New York, District of Columbia, Illinois).
Frequently Asked Questions
What is clinical trial NCT00666289 about?
NCT00666289 is a clinical study titled "Familial Myeloproliferative Disorders". Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the inv...
What is the current status of trial NCT00666289?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2008-03. Estimated completion is 2015-06-20.
What conditions does trial NCT00666289 study?
This clinical trial studies the following conditions: Polycythemia Vera, Essential Thrombocythemia, Idiopathic Myelofibrosis.
Who is sponsoring clinical trial NCT00666289?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666289 being conducted?
This trial has 6 study locations across District of Columbia, Illinois, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666289's enrollment target sits among peer trials
17 21st of 22 higher than 2 of 22 other Polycythemia Vera trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycythemia Vera trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
-
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
RECRUITING
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia